​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $79.50, with a high of $92.00 and a low of $67.00. This represents a 13.31% increase from the last price of $70.16.

$50 $59 $68 $77 $86 $95 High: $92 Avg: $79.5 Low: $67 Last Closed Price: $70.16

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (48.84%), 20 Hold (46.51%), 2 Sell (4.65%), and 0 Strong Sell (0.00%).

Buy
Total 43 0 2 20 21 Strong Sell Sell Hold Buy Strong Buy

INCY Price Target Upside V Benchmarks

TypeNameUpside
StockIncyte13.31%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts-112
Avg Price Target-$67.00$90.17
Last Closing Price$70.16$70.16$70.16
Upside/Downside--4.50%28.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2529151-27
Jun, 252716-126
May, 252816-127
Apr, 252816-127
Mar, 2511015-127
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 23, 2025RBC Capital$67.00$67.26-0.39%-4.50%
Mar 18, 2025Guggenheim$92.00$60.0053.33%31.13%
Oct 30, 2024Aaron KesslerSeaport Global$200.00$73.00173.97%185.06%
Oct 30, 2024Jay OlsonOppenheimer$82.00$73.6011.41%16.88%
Oct 30, 2024David LebowitzCitigroup$97.00$73.6031.79%38.26%
Oct 29, 2024Kelly ShiJefferies$84.00$73.6014.13%19.73%
Oct 29, 2024Tazeen AhmadBank of America Securities$90.00$73.6022.28%28.28%
Sep 30, 2024Andy ChenWolfe Research$84.00$66.1027.08%19.73%
Sep 16, 2024Tazeen AhmadBank of America Securities$68.00$63.566.99%-3.08%
Sep 16, 2024Salveen RichterGoldman Sachs$60.00$63.56-5.60%-14.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 23, 2025RBC CapitalSector PerformSector Performhold
Jun 03, 2025CitigroupBuyBuyhold
Mar 18, 2025GuggenheimBuyNeutraldowngrade
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 19, 2024OppenheimerOutperformOutperformhold
Nov 19, 2024BMO CapitalUnderperformUnderperformhold
Oct 30, 2024Seaport GlobalBuyupgrade
Oct 30, 2024RBC CapitalSector PerformSector Performhold
Oct 30, 2024BMO CapitalUnderperformUnderperformhold
Oct 30, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.36$4.30$1.53$2.67$0.16----
Avg Forecast$-1.31$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$-1.26$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Low Forecast$-1.41$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Surprise %3.82%66.67%-13.07%-25.83%-87.30%----

Revenue Forecast

$2B $3B $4B $5B $6B $7B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.67B$2.99B$3.39B$3.70B$4.24B----
Avg Forecast$2.54B$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$2.67B$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Low Forecast$2.45B$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Surprise %5.07%2.12%1.69%0.18%0.87%----

Net Income Forecast

$-5B $-3B $-2B $-200M $1B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-295.70M$948.58M$340.66M$597.60M$32.62M----
Avg Forecast$-4.06B$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$-3.13B$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Low Forecast$-5.00B$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Surprise %-92.72%-28.88%-76.49%--88.64%----

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 20 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 43 Wall Street analysts, averages $79.5 over the next 12 months. The price target range spans from $67 at the low end to $92 at the high end, suggesting a potential 13.31% change from the previous closing price of $70.16.

How does Incyte stock forecast compare to its benchmarks?

Incyte's stock forecast shows a 13.31% upside, underperforming the average forecast for the healthcare stocks sector (19.91%) and underperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • July 2025: 7.41% Strong Buy, 33.33% Buy, 55.56% Hold, 3.70% Sell, 0% Strong Sell.
  • June 2025: 7.69% Strong Buy, 26.92% Buy, 61.54% Hold, 0% Sell, 3.85% Strong Sell.
  • May 2025: 7.41% Strong Buy, 29.63% Buy, 59.26% Hold, 0% Sell, 3.70% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December 2025 is $5.9, marking a 3587.50% increase from the reported $0.16 in 2024. Estimates for the following years are $7.18 in 2026, $8.78 in 2027, and $10.69 in 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December 2025 is $4.64B, reflecting a 9.31% increase from the reported $4.24B in 2024. The forecast for 2026 is $5.05B, followed by $5.46B for 2027, and $5.94B for 2028.

What is Incyte’s net income forecast?

Incyte's net income forecast for the fiscal year ending in December 2025 stands at $1.34B, representing an 4014.50% increase from the reported $32.62M in 2024. Projections indicate $1.26B in 2026, $1.52B in 2027, and $2.41B in 2028.